Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Lyell Immunopharma presented updated safety data for ronde-cel in 108 patients with relapsed or refractory large B-cell lymphoma at the EHA 2026 Congress. The data showed no Grade 3 or higher Cytokine Release Syndrome (CRS) events and low rates of Grade 3 or higher Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), supporting the potential for outpatient administration. Translational insights highlighted the biological basis for durable responses, including enhanced memory potential of cytotoxic effector cells via CD62L+ enrichment and dual-targeting of CD19/CD20.
Key figures
- Drug Name
- rondecabtagene autoleucel (ronde-cel)
- Phase Of Trial
- Phase 1/2
- Patients treated
- 108
- Grade 3 plus crs rate
- 0%
- Manufacturing success rate
- 97%
- Grade 3 plus icans rate prophylaxis
- 8%
- Grade 3 plus icans rate no prophylaxis
- 16%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.